Reviewing Syndax Pharmaceuticals (SNDX) & Its Rivals

Syndax Pharmaceuticals (NASDAQ:SNDX) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Syndax Pharmaceuticals to similar companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Risk and Volatility

Syndax Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals’ peers have a beta of 1.14, meaning that their average stock price is 14% more volatile than the S&P 500.

Institutional & Insider Ownership

47.7% of shares of all “Biotechnology” companies are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Syndax Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-72.32%	-804.38%	-34.93%
Syndax Pharmaceuticals Competitors	-12,285.98%	-196.04%	-30.61%

Valuation & Earnings

This table compares Syndax Pharmaceuticals and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Syndax Pharmaceuticals	$289.68 million	-$285.42 million	-4.13
Syndax Pharmaceuticals Competitors	$729.47 million	$11.46 million	-14.96

Syndax Pharmaceuticals’ peers have higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Syndax Pharmaceuticals and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1	0	10	0	2.82
Syndax Pharmaceuticals Competitors	9904	15278	45629	1595	2.54

Syndax Pharmaceuticals presently has a consensus target price of $41.60, suggesting a potential upside of 327.10%. As a group, “Biotechnology” companies have a potential upside of 120.67%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than its peers.

Summary

Syndax Pharmaceuticals peers beat Syndax Pharmaceuticals on 8 of the 13 factors compared.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.